PCM
SRPT icon

Palisade Capital Management’s Sarepta Therapeutics SRPT Stock Holding History

Palisade Capital Management’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-5,587
Closed -$666K – 431
2019
Q1 		$666K Sell
5,587
-3,950
-41% -$508K 0.02% 355
2018
Q4 		$1.04M Buy
+9,537
New +$1.19M 0.04% 325
2014
Q4 		– Sell
-94,503
Closed -$1.99M – 497
2014
Q3 		$1.99M Buy
+94,503
New +$2.13M 0.05% 341

Other funds holding SRPT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Palisade Capital Management's SRPT Position: Q2 2019 in Review

Palisade Capital Management sold out of Sarepta Therapeutics (SRPT) in Q2 2019, closing a stake of 5,587 shares — an estimated $666K sold.

Palisade Capital Management first reported a position in SRPT in Q3 2014 and held it in 3 quarters. The position peaked at $1.99M in Q3 2014. 365 funds tracked by Wall St. Rank hold SRPT as of Q2 2019.

  • Palisade Capital Management reported no remaining Sarepta Therapeutics position as of Q2 2019 after selling out during the quarter.
  • Palisade Capital Management sold 5,587 Sarepta Therapeutics shares in Q2 2019, an estimated $666K.
  • Palisade Capital Management first reported a position in Sarepta Therapeutics in Q3 2014 and held it in 3 quarters.
  • Palisade Capital Management's Sarepta Therapeutics position peaked at $1.99M in Q3 2014.
  • 365 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2019.

Based on Palisade Capital Management's 13F filing for Q2 2019, filed 6 Aug 2019.